Aligos Q4 net loss $27.9M ($0.22/sh); cash $135.7M; HERALD data expected Q4 2024

Aligos Therapeutics, Inc.

Cash and investments $135.7M as of Dec 31, 2023; raised $92.1M in Oct 2023 PIPE; runway through end of 2025.
Q4 2023 net loss $27.9M ($0.22/sh) vs $21.9M ($0.51/sh) in Q4 2022; full year net loss $87.7M ($1.36/sh).
ALG-055009 Phase 2a HERALD (MASH) first subject dosed expected Q2 2024; topline data anticipated Q4 2024.
ALG-000184 (CHB) Phase 1b continues; interim data presentations planned at APASL, EASL, AASLD 2024.
ALG-097558 pan-coronavirus protease inhibitor Phase 1 nearing completion; topline data at ECCMID April 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported the year ended December 31, 2023 results: net income $87.7 million, EPS $(1.36).

Period: the year ended December 31, 2023
Net income: $87.7 million
EPS: $(1.36)
Result: reported results

Exact text from the filing

Net losses for the year ended December 31, 2023 were $87.7 million or basic and diluted net loss per common share of $(1.36), compared to net losses of $96.0 million or basic and diluted net loss per common share of $(2.25) for the year ended December 31, 2022.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Aligos Therapeutics, Inc. reported the three months ended December 31, 2023 results: net income $27.9 million, EPS $(0.22).

Period: the three months ended December 31, 2023
Net income: $27.9 million
EPS: $(0.22)
Result: reported results

Exact text from the filing

Net losses for the three months ended December 31, 2023 were $27.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $21.9 million or basic and diluted net loss per common share of $(0.51) for the three months ended December 31, 2022.

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-001294

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.